EP0023359A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Powdery pharmaceutical composition and powdery preparation for application to the nasal mucosa, and method for administration thereof
Assignee: Teijin Ltd
•
Filing: 1980-07-29
•
Granted: —
•
Expires: 2000-07-29
Abstract
Abstract A powdery pharmaceutical composition and a powdery preparation in unit dosage form for application to the mucosa of the nasal cavity, at least about 90% of which consists of particles having an effective particle diameter of about 20 to about250 microns, said composition comprising a lower alkyl ether or cellulose having a viscosity, determined at about 376C for a 2% aqueous solution thereof, of at least about 5 centipoises and a pharmaceutically effective amount of a drug; and a method for treating or preventing a human nasal disease, which comprises administering a powdery preparation in unit dosage form to the nasal cavity of a human being requiring treatment or prevention of a nasal disease through his nostrils.
Inventors
- 👤 Yoshiki Suzuki
- 👤 Hiroshi Ikura
- 👤 Gentaro Yamashita
- 👤 Tsuneji Nagai
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-05 05:42
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0043
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
70 words
A powdery pharmaceutical composition for application to the mucosa of the nasal cavity, at least about 90% of which consists of particles having an effective particle diameter of about 20 to about 250 microns, said composition comprising a lower alkyl ether of cellulose having a viscosity, determined at about 37°C for a 2% aqueous solution thereof, of at least about 5 centipoises and a pharmaceutically effective amount of a drug.
Claim 2
Dependent Claim
70 words
A powdery pharmaceutical composition for application to the mucosa of the nasal cavity, at least about 90% of which consists of particles having an effective particle diameter of about 20 to about 250 microns, said composition comprising a lower alkyl ether of cellulose having a viscosity, determined at about 37°C for a 2% aqueous solution thereof, of at least about 5 centipoises and a pharmaceutically effective amount of a drug.
Claim 3
Dependent Claim
60 words
The composition of claim 1 wherein the lower alkyl group of said lower alkyl ether of cellulose is at least one member selected from the class consisting - of a methyl group, hydroxy lower alkyl groups having 2 or 3 carbon atoms and carboxylate groups formed between alkali metals and carboxy lower alkyl groups having 2 or 3 carbon atoms.
Claim 4
Dependent Claim
27 words
The composition of claim 2 wherein said lower alkyl ether of cellulose is methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethylhydroxyethyl cellulose or sodium carboxymethyl cellulose.
Claim 5
Dependent Claim
20 words
The composition of claim 2 wherein said lower alkyl ether of cellulose is methyl cellulose, hydroxypropyl cellulose or hydroxypropylmethyl cellulose.
Claim 6
Dependent Claim
15 words
The composition of claim 2 wherein said lower alkyl ether of cellulose is hydroxypropyl cellulose.
Claim 7
Dependent Claim
34 words
The composition of claim 1 wherein said lower alkyl ether of cellulose has a viscosity, determined at about 37°C for a 2% by weight aqueous solution thereof, of about 5 to about 5000 centipoises.
Claim 8
Dependent Claim
28 words
The composition of claim 1 at least about 90% by weight of which consists of particles having an effective particle diameter of about 20 to about 150 microns.
Claim 9
Dependent Claim
61 words
The composition of any one of claims 1 to 7 wherein said drug forms particles independent from particles of said cellulose ether, or adheres to the surface of the particles of said cellulose ether, or is dispersed as particles forming a discrete phase in the particles of said cellulose ether, or is intimately dispersed in the particles of said cellulose ether.
Claim 10
Dependent Claim
23 words
The composition of any one of claims 1 to 8 wherein said drug is an agent for treating or preventing a nasal disease.
Claim 11
Dependent Claim
37 words
The composition of any one of claims 1 to 8 wherein said drug is selected from the group consisting of a steroidal anti-inflammatory agent, a nonsteroidal anti-inflammatory agent, an anti-histaminic agent, an anti-allergic agents and a vasoconstrictor.
Claim 12
Dependent Claim
16 words
The composition of claim 10 wherein said steroidal anti-inflammatory agent is triamcinolone acetonide or beclomethasone dipropionate.
Claim 13
Dependent Claim
13 words
The composition of claim 10 wherein said non- steroidal anti-inflammatory agent is indomethacine.
Claim 14
Dependent Claim
15 words
The composition of claim 10 wherein said anti- histaminic agent is chloropheniramine maleate or clemastine.
Claim 15
Dependent Claim
14 words
The composition of claim 10 wherein said anti-allergic agent is ephedrine or sodium cromoglycate.
Claim 16
Dependent Claim
11 words
The composition of claim 10 wherein said vasoconstrictor is naphazoline nitrate.
Claim 17
Dependent Claim
80 words
A powdery preparation in unit dosage form for application to the mucosa of the nasal cavity, at least about 90% by weight of which consists of particles having an effective particle diameter of about 20 to about 250 microns, said powdery preparation comprising a lower alkyl ether of cellulose having a viscosity, determined at about 37 0 C for a 2% by weight aqueous solution thereof, of at least about 5 centipoises and a pharmaceutically effective amount of a drug.
Claim 18
Dependent Claim
80 words
A powdery preparation in unit dosage form for application to the mucosa of the nasal cavity, at least about 90% by weight of which consists of particles having an effective particle diameter of about 20 to about 250 microns, said powdery preparation comprising a lower alkyl ether of cellulose having a viscosity, determined at about 37 0 C for a 2% by weight aqueous solution thereof, of at least about 5 centipoises and a pharmaceutically effective amount of a drug.
Claim 19
Dependent Claim
33 words
The powdery preparation of claim 16 wherein said drug is a steroidal anti-inflammatory agent in an amount of about 0.005 to about 1% by weight based on the weight of the powdery preparation.
Claim 20
Dependent Claim
32 words
The powdery preparation of claim 16 wherein said drug is an anti-histaminic agent in an amount of about 0.1 to about 20% by weight based on the weight of the powdery preparation.
Claim 21
Dependent Claim
17 words
The powdery preparation of any one of claims 16 to 18 which is filled in a capsule.
Claim 22
Dependent Claim
14 words
The powdery preparation of claim 19 wherein said capsule is a hard gelatin capsule.
Claim 23
Independent Claim
114 words
A method for treating or preventing a human nasal disease, which comprises administering a powdery prepara- tion in unit dosage form to the nasal cavity of a human being requiring treatment or prevention of a nasal disease through his nostrils, thereby adhering said powdery preparation to the nasal mucosa, said powdery preparation comprising a lower alkyl ether of cellulose having a viscosity, determined at about 37°C for a 2% by weight aqueous solution thereof, of at least about 5 centipoises and an agent for treating or preventing the nasal disease, at least about 90% by weight of said preparation consisting of particles having an effective particle diameter of about 20 to about 250 microns.
Claim 24
Independent Claim
114 words
A method for treating or preventing a human nasal disease, which comprises administering a powdery prepara- tion in unit dosage form to the nasal cavity of a human being requiring treatment or prevention of a nasal disease through his nostrils, thereby adhering said powdery preparation to the nasal mucosa, said powdery preparation comprising a lower alkyl ether of cellulose having a viscosity, determined at about 37°C for a 2% by weight aqueous solution thereof, of at least about 5 centipoises and an agent for treating or preventing the nasal disease, at least about 90% by weight of said preparation consisting of particles having an effective particle diameter of about 20 to about 250 microns.
Claim 25
Dependent Claim
20 words
The method of claim 21 wherein the administration of said powdery preparation to the nasal cavity is performed by spraying.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.